retatrutide clinical trial dose trials efficacy (RETA) is one of the most promising investigational peptides in obesity research— retatrutide clinical trial dosing schedule

The guidelines state, GLP-1 RAs may be considered for weight-loss in patients who have completed cancer therapy and may be considered with caution for patients on stable endocrine-based cancer therapies based on limited observational safety data. They also say, GLP-1 RAs cannot be recommended currently for patients receiving or initiating chemotherapies and/or immunotherapies due to lack of safety and outcomes data. Iyengar is director of Survivorship Services at Winship Cancer Institute of Emory University, a clinical member of Winships Glenn Family Breast Center, an associate professor and co-director of the Breast Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, and co-editor-in-chief of the journal ONCOLOGY

Our understanding as to why these medications are so effective continues to evolve

These findings suggest a potential, albeit subtle, influence of GLP1R expression on patient outcomes

Headaches are also a common side effect of PT-141, but they are usually mild and go away within a few hours

dehydration causing kidney issues